News that AstraZeneca (NYSE:AZN) has resumed late-stage trials of its Covid-19 vaccine candidate, coupled with Pfizer (NYSE:PFE) CEO Albert Bourla saying its candidate has a “good chance” of submitting key data from late-stage trials by the end of October, has created a more positive attitude to risk, hitting the dollar. “Despite its profound fall in the past few days, we expect the pressure on GBP to continue building ... as until-recently complacent investors adjust to the new reality of a heightened no-deal Brexit risk and start/continue building GBP shorts,” ING added.
At 2:50 AM ET (0650 GMT), the Dollar Index, which tracks the greenback against a basket of six other currencies, was down 0.2% at 93.090, with EUR/USD up 0.2% at 1.1829. The euro has pushed higher, helped by Bloomberg News reporting that ECB officials are growing more confident in the bloc's economic outlook. With this in mind, traders will be following this ECB meeting closely.